The frequency of apneas and hypopneas during sleep, quantified as the Apnea-Hypopnea Index (AHI), is a crucial metric for assessing the effectiveness of Continuous Positive Airway Pressure (CPAP) therapy. An elevated AHI, measured in events per hour, indicates that breathing disruptions persist despite CPAP use. For example, an AHI above 5 while on CPAP suggests suboptimal treatment, warranting further investigation and adjustment.
Maintaining a low AHI during CPAP therapy is paramount for mitigating the long-term health consequences associated with sleep apnea, such as cardiovascular strain, cognitive impairment, and daytime fatigue. Historically, titration studies in sleep laboratories were the primary method for optimizing CPAP settings. However, advancements in CPAP technology and remote monitoring now offer increased flexibility and personalized adjustments to enhance therapeutic efficacy.
